Medicare AdvantageBilling CodesMedium impact
MA07.032a, Tumor Treating Fields
Independence Blue Cross·Oncology, Neurology, Neurosurgery +1 more·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jul 23, 2026
Summary
Independence Blue Cross Medicare Advantage has reissued MA07.032a to add CPT code 1025T (Alternating electric fields dosimetry and delivery) effective 01/01/2026. This code covers patient-specific Tumor Treating Fields (TTFields) simulation modeling and array placement verification for newly diagnosed glioblastoma. The policy maintains existing coverage criteria and continues to exclude recurrent glioblastoma and patients with implanted devices.
Action Required
By December 31, 2025: Billing team must update billing software and fee schedules to recognize and process CPT code 1025T as medically necessary for newly diagnosed glioblastoma cases under Medicare Advantage plans. Ensure that claims submission includes confirmation that patient meets all coverage criteria: histologically confirmed supratentorial glioblastoma (WHO grade IV), Karnofsky Performance Score above 70, completed standard therapeutic options, no RANO-assessed progression, and documented willingness to use device 18+ hours daily. Continue monitoring for continuation coverage beyond 3 months, which requires objective clinical assessment documentation. Confirm that A4555 (replacement electrodes) continues to be marked as not separately reimbursable. Educate providers on the expanded coding options for TTFields treatment documentation.